19 reports of this reaction
4.5% of all FLUPHENAZINE HYDROCHLORIDE reports
#1 most reported adverse reaction
SEDATION is the #1 most commonly reported adverse reaction for FLUPHENAZINE HYDROCHLORIDE, manufactured by Rising Pharma Holdings, Inc.. There are 19 FDA adverse event reports linking FLUPHENAZINE HYDROCHLORIDE to SEDATION. This represents approximately 4.5% of all 426 adverse event reports for this drug.
Patients taking FLUPHENAZINE HYDROCHLORIDE who experience sedation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEDATION is moderately reported among FLUPHENAZINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to sedation, the following adverse reactions have been reported for FLUPHENAZINE HYDROCHLORIDE:
The following drugs have also been linked to sedation in FDA adverse event reports:
SEDATION has been reported as an adverse event in 19 FDA reports for FLUPHENAZINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEDATION accounts for approximately 4.5% of all adverse event reports for FLUPHENAZINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience sedation while taking FLUPHENAZINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.